Please login to the form below

Not currently logged in
Email:
Password:

Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication

IpsenIpsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial results.

The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients with advanced hepatocellular carcinoma (HCC), the sixth most common form of cancer with around 800,000 new cases diagnosed each year.

Data showed cabozantinib provided a ‘statistically significant’ and ‘clinically meaningful’ improvement of overall survival (OS) compared to placebo.

Alexandre Lebeaut, Ipsen’s chief scientific officer, said: “Liver cancer is one of the leading causes of cancer deaths worldwide and more effective treatment options are urgently needed.

“We are pleased to report that in the CELESTIAL clinical study cabozantinib has been shown to provide a survival benefit and therefore has the potential to bring a new oral systemic treatment to previously treated patients with advanced liver cancer.”

The once-daily oral drug comprises of a small molecule inhibitor of receptors - including VEGFR, MET, AXL and RET - which are involved in normal cellular function and pathologic processes such as invasiveness, metastasis and drug resistance.

The duo has already seen success with the drug after gaining a US FDA approval to treat patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Additionally, the drug received the European go ahead for the treatment of RCC in adults who have received prior vascular endothelial growth factor (VEGF)-targeted therapy.

Ipsen will now “evaluate potential next steps in the development strategy” for cabozantinib outside the US and Japan as a treatment for advanced HCC in patients who have been previously treated.

Article by
Gemma Jones

17th October 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics